A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05593094
• Other study ID #: ZN-A-1041-101-US
• Status: Recruiting
• Phase: Phase 1
• Start date: October 15, 2020
• Est. completion date: October 30, 2024

Study information

• Verified date: July 2023
• Source: Suzhou Zanrong Pharma Limited
• Contact: Ding Zhou, Ph.D
• Phone: (86)-13916360900
• Email: ding.zhou[@]zionpharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases.

The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Description:

Phase 1a of the study will adopt the "modified 3+3" dose escalation design with a total of 7 planned dose levels. Patients with HER2-positive advanced solid tumor (including those with brain metastases) will be enrolled to receive a single-dose administration of ZN-A-1041 followed by multiple-dose administration of ZN-A-1041.Phase 1b of the study will adopt the "traditional 3+3" dose escalation design. The dose levels will be based on the results of the Phase 1a study and the results of a food effect study. In Phase 1b, patients with unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis will be enrolled in three arms: Arm1 will receive multiple doses of ZN-A-1041 in combination with T-DM1; Arm2 will receive multiple doses of ZN-A-1041 in combination with T-DXd. Arm 3 will receive multiple doses of ZN-A-1041 in combination with PHESGO or Herceptin plus Perjeta after Herceptin plus Perjeta and 4-8-cycle treatment of taxane Patients will be assigned to an appropriate arm by the sponsor and the investigator based on his/her eligibility at the time of consent. Patients with unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis are planned to be enrolled in Phase 1c of the study: Arm1 will receive multiple doses of ZN-A-1041 in combination with T-DM1; Arm2 will receive multiple doses of ZN-A-1041 in combination with T-DXd; Arm 3 will receive multiple doses of ZN-A-1041 in combination with PHESGO or Herceptin plus Perjeta after Herceptin plus Perjeta and 4-8-cycle treatment of taxane. Patients will be assigned to an appropriate arm by the sponsor and the investigator based on his/her eligibility at the time of consent. Arm1 of Phase 1c can start independently after the DLT observation period of the last patient in Phase 1b Arm1. Arm 2 of Phase 1c can start independently after the DLT observation of the last patient in Phase 1b Arm 2. Arm 3 of Phase 1c can start independently after the DLT observation of the last patient in Phase 1b Arm 3. The dose levels used in Phase 1c will be based on the recommended doses obtained from the Phase 1b study.

Each phase of the study includes a screening period (from 28 days prior to the first administration of the study drug), a treatment period (until there are no clinical benefits as deemed by the Investigator, disease progression, death, intolerable toxicity, withdrawal of informed consent, loss of follow-up, or the start of new anti-tumor treatment), and a follow-up period (until 28 days after the last administration of the study drug). During the trial, the safety, tolerability, PK and efficacy data of ZN-A-1041 as monotherapy and in combination in the subjects will be collected and analyzed, thereby providing RP2D for subsequent future clinical trials.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 210
• Est. completion date: October 30, 2024
• Est. primary completion date: October 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

• Inclusion Criteria:

1. ECOG performance status of 0 to 1

2. HER2 positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++).

3. Phase 1a study will enroll patients with unresectable or metastatic HER2-positive advanced solid tumor.

For patients who have no brain metastases, the following criteria should be met:

1. Patients should be relapsed or refractory to existing therapy(ies) or have been intolerant of such therapies

2. Patients with HER2-positive breast cancer should have previously received Trastuzumab, Pertuzumab, Trastuzumab emtansine(T-DM1) and a taxane.

3. Patients with HER2-positive gastric cancer must have previously received trastuzumab.

4. Have measurable or non-measurable disease assessable by RECIST 1.1.

For patients with brain metastasis, the following criteria should be met:

1. Patients with HER2-positive breast cancer must have received prior treatment with Trastuzumab, Pertuzumab and T-DM1, and a taxane or patient declined the above treatment.

2. Patients with HER2-positive gastric cancer must have previously received Trastuzumab

3. Do not require immediate local treatment during the trial period, and meet either of the following two criteria: i) For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT and 2 weeks from SRS; ii) Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period.

For patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks.

4. Phase 1b and Phase 1c study will enroll patients with unresectable locally advanced or metastatic HER2+ breast cancer.

For patients who have no brain metastases, the following criteria should be met:

1. For arm 1 and arm 2, patients should be relapsed or refractory to existing therapy(ies), with a history of prior treatment with trastuzumab and a taxane. For arm3, patients have received 4-8 cycles (21-day cycles) of previous treatment with trastuzumab, pertuzumab, and taxane as first-line therapy for advanced HER2+ breast cancer with no evidence of disease progression.

2. Have measurable or non-measurable disease assessable by RECIST 1.1

For patients with brain metastasis, the following criteria should be met:

1. For arm 1 and arm 2, patients should be relapsed or refractory to existing therapy(ies), with a history of prior treatment with trastuzumab and a taxane. For arm3, patients have received 4-8 cycles (21-day cycles) of previous treatment with trastuzumab, pertuzumab, and taxane as first-line therapy for advanced HER2+ breast cancer with no evidence of disease progression.

2. Do not require immediate local treatment during the trial period, and meet either of the following two criteria: i) For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT, 2 weeks from SRS and 4 weeks from surgery; ii) Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period.

5. Suspected or confirmed leptomeningeal metastasis are allowed in Phase 1b, but not allowed in Phase 1c.

6. In Phase 1b arm1 and arm2, patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. For arm3, patients should not have prior treatment for unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis, except for ongoing Herceptin, Perjeta or PHESGO and taxane.

7. In Phase 1c arm1 and arm2, Patients should not have received prior treatment with tucatinib, afatinib, or any other investigational anti-HER2, anti-EGFR, or HER2 TKI agent. Prior treatment with lapatinib or neratinib within 12 months of starting study treatment (except in cases where they were given for = 21 days and was discontinued for reasons other than disease progression or severe toxicity). Prior treatment with pyrotinib for recurrent of mBC (except in cases where pyrotinib was given for = 21 days and was discontinued for reasons other than disease progression or severe toxicity). For arm3, patients should not have prior treatment for unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis, except for ongoing Herceptin, Perjeta or PHESGO and taxane.

• Exclusion Criteria:

1. Subjects who have participated in any clinical study or received any clinical study drug within 4 weeks prior to the first administration except for on-going Herceptin, Perjeta or PHESGO in arm3

2. CNS Exclusion - Based on screening brain MRI and clinical assessment

1. Progressive neurologic impairment or increased intracranial pressure (including nausea, vomiting, blurred vision, headache, epilepsy, etc.)

2. Any intracranial lesion thought to require immediate local therapy

3. Require antiepileptic treatment (except for these patients with stable seizures require continuous Levetiracetam therapy).

4. Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)

Related Conditions & MeSH terms

• Advanced Solid Tumors
• HER2-positive Breast Cancer
• Neoplasms

Intervention

Drug:
• ZN-A-1041 50mg BID
twice a day (BID) via oral administration
• ZN-A-1041 100mg BID
twice a day (BID) via oral administration
• ZN-A-1041 200mg BID
twice a day (BID) via oral administration
• ZN-A-1041 400mg BID
twice a day (BID) via oral administration
• ZN-A-1041 600mg BID
twice a day (BID) via oral administration
• ZN-A-1041 800mg BID
twice a day (BID) via oral administration
• ZN-A-1041 1000mg BID
twice a day (BID) via oral administration
• ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b
ZN-A-1041: twice a day (BID) via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
• ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b
ZN-A-1041: twice a day (BID) via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
• ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b
ZN-A-1041: twice a day (BID) via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
• ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c
ZN-A-1041: twice a day (BID) via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
• ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c
ZN-A-1041: twice a day (BID) via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
• ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
ZN-A-1041: twice a day (BID) via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Dana-Farber Cancer Insitute	Boston	Massachusetts
United States	Barbara Ann Karmanos Cancer center	Detroit	Michigan
United States	Duke Cancer Institute	Durham	North Carolina
United States	Md Anderson Cancer center	Houston	Texas
United States	ACRC/Arizona Clinical Research Center, Inc	Tucson	Arizona
United States	Innovative Clinical Research Institute	Whittier	California

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou Zanrong Pharma Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Incidence of Treatment-Emergent Adverse Events of ZN-A-1041 as a monotherapy in Phase 1a	Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.	23 days
Primary	The Incidence of Treatment-Emergent Adverse Events of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta	Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.	21 days
Primary	RP2D Dose	To evaluate the safety of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta in patients on the RP2D Dose	through study completion, an average of 1 year
Secondary	AUC. Plasma level of ZN-A-1041 and its main metabolites Phase 1a, phase 1b and 1c	To assess the AUC of ZN-A-1041 and its major metabolites	From baseline to Day 8
Secondary	Cmax. Plasma level of ZN-A-1041 and its main metabolites Phase 1a, phase 1b and 1c	To assess the Cmax of ZN-A-1041 and its major metabolites	From baseline to Day 8
Secondary	Tmax. Plasma level of ZN-A-1041 and its main metabolites Phase 1a, phase 1b and 1c	To assess the Tmax of ZN-A-1041 and its major metabolites	From baseline to Day 8
Secondary	overall Response Rate (ORR)	The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a,phase 1b and 1c	through study completion, an average of 1 year
Secondary	Progression free survival(PFS)	The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a,phase 1b and 1c	through study completion, an average of 1 year